Srivastava et al., 2019 - Google Patents
A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trialsSrivastava et al., 2019
View HTML- Document ID
- 4857833850344414721
- Author
- Srivastava S
- Jackson C
- Kim T
- Choi J
- Lim M
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Glioblastoma (GBM) is the most common and fatal primary central nervous system malignancy in adults with a median survival of less than 15 months. Surgery, radiation, and chemotherapy are the standard of care and provide modest benefits in survival, but tumor …
- 210000004443 Dendritic Cells 0 title abstract description 277
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Srivastava et al. | A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials | |
| Hato et al. | Dendritic cells in cancer immunology and immunotherapy | |
| Yao et al. | DC-derived exosomes for cancer immunotherapy | |
| Kciuk et al. | Recent advances in molecular mechanisms of cancer immunotherapy | |
| Lee et al. | Dendritic cell vaccines: a shift from conventional approach to new generations | |
| Carlson et al. | Talkin’toxins: from Coley’s to modern cancer immunotherapy | |
| Del Prete et al. | Functional role of dendritic cell subsets in cancer progression and clinical implications | |
| Schirrmacher | Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory | |
| Matsuo et al. | Recent progress in dendritic cell-based cancer immunotherapy | |
| Patente et al. | Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy | |
| Fu et al. | Plasmacytoid dendritic cells and cancer immunotherapy | |
| Patel et al. | The future of glioblastoma therapy: synergism of standard of care and immunotherapy | |
| Guillerme et al. | Measles virus vaccine–infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells | |
| Audsley et al. | Cross-presenting XCR1+ dendritic cells as targets for cancer immunotherapy | |
| Nava et al. | Dendritic cells and cancer immunotherapy: the adjuvant effect | |
| Economopoulou et al. | Tumor microenvironment and immunotherapy response in head and neck cancer | |
| Allen et al. | Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches | |
| Fournier et al. | Oncolytic Newcastle disease virus as cutting edge between tumor and host | |
| Kim et al. | Dendritic cells in oncolytic virus-based anti-cancer therapy | |
| Hernández et al. | Plasmacytoid dendritic cells as a novel cell-based cancer immunotherapy | |
| CN101511384A (en) | Dendritic cells made with GM-CSF and interferon-alpha and loaded with heat-treated and killed cancer cells | |
| Caro et al. | Dendritic cell vaccines: A promising approach in the fight against ovarian cancer | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| Allen et al. | The clinical implications of antitumor immunity in head and neck cancer | |
| Sittig et al. | Primary human blood dendritic cells for Cancer immunotherapy—tailoring the immune response by dendritic cell maturation |